Position in OGN
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$91,233
-$17,973 QoQ
Shares Held
15,231
0.0% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in OGN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026EntryPoint Capital, LLC holds $4,359,430 across 8 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
13,595 | $1,717,592 | |
| 2 | PFE |
Pfizer Inc
|
40,976 | $986,702 | |
| 3 | BIIB |
Biogen Inc.
|
1,716 | $370,758 | |
| 4 | GSK |
GSK plc
|
6,632 | $347,649 | |
| 5 | NVS |
Novartis AG
|
1,936 | $303,409 | |
| 6 | AMGN |
Amgen Inc
|
654 | $236,826 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
3,499 | $201,612 | |
| 8 | AMRN |
Amarin Corp Plc\Uk
|
12,226 | $194,882 |
All Filings in OGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $91,233 | 15,231 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $109,206 | 15,231 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $127,316 | 11,921 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $106,431 | 10,995 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $169,626 | 11,392 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $416,849 | 27,939 | Shares | Sole | 2025-02-11 | |
| No filing history on record for this holder in this stock. | ||||||